CN101896065B - 新的sEH抑制剂及其用途 - Google Patents
新的sEH抑制剂及其用途 Download PDFInfo
- Publication number
- CN101896065B CN101896065B CN200880120430XA CN200880120430A CN101896065B CN 101896065 B CN101896065 B CN 101896065B CN 200880120430X A CN200880120430X A CN 200880120430XA CN 200880120430 A CN200880120430 A CN 200880120430A CN 101896065 B CN101896065 B CN 101896065B
- Authority
- CN
- China
- Prior art keywords
- methyl
- amino
- phenyl
- triazin
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PPQIYRKVGVMANU-TYKWCNGQSA-N CNc1nc(-c2ccccc2)nc(N(C)[C@H](CC2)CC[C@H]2/C(/NCc2c(C(F)(F)F)cccc2)=[O]\C)n1 Chemical compound CNc1nc(-c2ccccc2)nc(N(C)[C@H](CC2)CC[C@H]2/C(/NCc2c(C(F)(F)F)cccc2)=[O]\C)n1 PPQIYRKVGVMANU-TYKWCNGQSA-N 0.000 description 1
- XOACBHGHDRGBJK-PUZFROQSSA-N CNc1nc(-c2ccccc2)nc(N(C)[C@H](CC2)CC[C@H]2C(NCc(cccc2)c2OC(F)(F)F)=O)n1 Chemical compound CNc1nc(-c2ccccc2)nc(N(C)[C@H](CC2)CC[C@H]2C(NCc(cccc2)c2OC(F)(F)F)=O)n1 XOACBHGHDRGBJK-PUZFROQSSA-N 0.000 description 1
- 0 CS(=O)#*c1cc(Cl)c(CN)cc1 Chemical compound CS(=O)#*c1cc(Cl)c(CN)cc1 0.000 description 1
- HKGYDNVWQRUVJT-XBXGTLAGSA-N Cc1nc(Cl)nc(N[C@H](CC2)CC[C@H]2C(NCc2c(C(F)(F)F)cccc2)=O)n1 Chemical compound Cc1nc(Cl)nc(N[C@H](CC2)CC[C@H]2C(NCc2c(C(F)(F)F)cccc2)=O)n1 HKGYDNVWQRUVJT-XBXGTLAGSA-N 0.000 description 1
- IQVMHMUHFMYGJW-IZAXUBKRSA-N Cc1nc(N2CCCCC2)nc(N[C@H](CC2)CC[C@H]2C(NCc2ccccc2C(F)(F)F)=O)n1 Chemical compound Cc1nc(N2CCCCC2)nc(N[C@H](CC2)CC[C@H]2C(NCc2ccccc2C(F)(F)F)=O)n1 IQVMHMUHFMYGJW-IZAXUBKRSA-N 0.000 description 1
- GGCPBBSKMSLCMD-FZNQNYSPSA-N Cc1nc(NCCO)nc(N[C@H](CC2)CC[C@H]2C(NCc2c(C(F)(F)F)cccc2)=O)n1 Chemical compound Cc1nc(NCCO)nc(N[C@H](CC2)CC[C@H]2C(NCc2c(C(F)(F)F)cccc2)=O)n1 GGCPBBSKMSLCMD-FZNQNYSPSA-N 0.000 description 1
- UMFDLCWSALJEIZ-WOVMCDHWSA-N Cc1nc(NCCOC)nc(N[C@H](CC2)CC[C@H]2C(NCc2c(C(F)(F)F)cccc2)=O)n1 Chemical compound Cc1nc(NCCOC)nc(N[C@H](CC2)CC[C@H]2C(NCc2c(C(F)(F)F)cccc2)=O)n1 UMFDLCWSALJEIZ-WOVMCDHWSA-N 0.000 description 1
- WCBVBEQNZPEIDX-UHFFFAOYSA-N NCc(c(OC(F)(F)F)c1)ccc1Br Chemical compound NCc(c(OC(F)(F)F)c1)ccc1Br WCBVBEQNZPEIDX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97915407P | 2007-10-11 | 2007-10-11 | |
| US60/979,154 | 2007-10-11 | ||
| PCT/US2008/079517 WO2009049157A1 (en) | 2007-10-11 | 2008-10-10 | Novel seh inhibitors and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101896065A CN101896065A (zh) | 2010-11-24 |
| CN101896065B true CN101896065B (zh) | 2013-12-18 |
Family
ID=40549589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880120430XA Active CN101896065B (zh) | 2007-10-11 | 2008-10-10 | 新的sEH抑制剂及其用途 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8173805B2 (https=) |
| EP (1) | EP2214487B1 (https=) |
| JP (1) | JP5372943B2 (https=) |
| KR (1) | KR101546111B1 (https=) |
| CN (1) | CN101896065B (https=) |
| AU (1) | AU2008310732B2 (https=) |
| BR (1) | BRPI0817542A2 (https=) |
| CA (1) | CA2702265C (https=) |
| CO (1) | CO6270285A2 (https=) |
| CR (1) | CR11423A (https=) |
| CY (1) | CY1114865T1 (https=) |
| DK (1) | DK2214487T3 (https=) |
| DO (1) | DOP2010000101A (https=) |
| EA (1) | EA018414B1 (https=) |
| ES (1) | ES2445444T3 (https=) |
| HR (1) | HRP20140105T1 (https=) |
| IL (1) | IL204889A (https=) |
| MA (1) | MA31761B1 (https=) |
| MX (1) | MX2010003942A (https=) |
| MY (1) | MY157116A (https=) |
| NZ (1) | NZ584471A (https=) |
| PL (1) | PL2214487T3 (https=) |
| PT (1) | PT2214487E (https=) |
| RS (1) | RS53180B (https=) |
| SI (1) | SI2214487T1 (https=) |
| UA (1) | UA107444C2 (https=) |
| WO (1) | WO2009049157A1 (https=) |
| ZA (1) | ZA201002465B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994317B2 (en) | 2006-11-03 | 2011-08-09 | GlaxoSmithKline, LLC | sEH inhibitors and their use |
| WO2009049165A1 (en) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| JP5372943B2 (ja) | 2007-10-11 | 2013-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015104422A1 (en) | 2014-01-13 | 2015-07-16 | Basf Se | Dihydrothiophene compounds for controlling invertebrate pests |
| WO2015155129A1 (en) * | 2014-04-07 | 2015-10-15 | Basf Se | Diaminotriazine compound |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2020074549A1 (en) * | 2018-10-10 | 2020-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction |
| EP4618985A1 (en) | 2022-11-18 | 2025-09-24 | Universitat De Barcelona | Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
| WO2026058000A2 (en) | 2024-09-13 | 2026-03-19 | Ucl Business Ltd | Methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028467A1 (en) * | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| WO2007106525A1 (en) * | 2006-03-13 | 2007-09-20 | The Regents Of The University Of California | Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases |
| WO2008105968A1 (en) * | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420283A (en) * | 1993-08-02 | 1995-05-30 | Pfizer Inc. | Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide |
| WO2000038683A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| EP1790344B1 (en) * | 2000-07-07 | 2011-02-23 | Spectrum Pharmaceuticals, Inc. | Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| US6451814B1 (en) * | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| US20020091133A1 (en) * | 2000-12-12 | 2002-07-11 | Eve M. Taylor | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
| NZ526472A (en) * | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| CA2449486A1 (en) * | 2001-06-29 | 2003-01-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of using soluble epoxide hydrolase inhibitors |
| US20030055249A1 (en) | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| KR100875362B1 (ko) * | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
| EP1505972A2 (en) | 2002-05-16 | 2005-02-16 | Pharmacia Corporation | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| AU2004274309B2 (en) * | 2003-09-22 | 2010-04-08 | Msd K.K. | Novel piperidine derivative |
| GB0401269D0 (en) | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| WO2006037117A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| EP1831181A2 (en) | 2004-12-14 | 2007-09-12 | Vertex Pharmaceuticals Incorporated | Pyrimidine inhibitors of erk protein kinase and uses thereof |
| WO2006121719A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International, Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| CA2622754A1 (en) * | 2005-10-07 | 2007-04-19 | Boehringer Ingelheim International Gmbh | N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors |
| WO2007098352A2 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| WO2009049154A1 (en) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| JP5372943B2 (ja) | 2007-10-11 | 2013-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| WO2009049165A1 (en) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| JPWO2009048154A1 (ja) | 2007-10-12 | 2011-02-24 | 日本電気株式会社 | 半導体装置及びその設計方法 |
| WO2009070497A1 (en) | 2007-11-28 | 2009-06-04 | Smithkline Beecham Corporation | SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE |
| EP2224928A4 (en) | 2007-12-06 | 2012-02-15 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
| WO2009097474A1 (en) | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| EP2240025A4 (en) * | 2008-01-30 | 2012-03-28 | Glaxosmithkline Llc | NEW SEE INHIBITORS AND THEIR USE |
| WO2009097476A1 (en) | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| WO2010011917A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | SEH AND 11β-HSD1 DUAL INHIBITORS |
-
2008
- 2008-10-10 JP JP2010529081A patent/JP5372943B2/ja active Active
- 2008-10-10 CA CA2702265A patent/CA2702265C/en active Active
- 2008-10-10 WO PCT/US2008/079517 patent/WO2009049157A1/en not_active Ceased
- 2008-10-10 PT PT88383146T patent/PT2214487E/pt unknown
- 2008-10-10 DK DK08838314.6T patent/DK2214487T3/da active
- 2008-10-10 SI SI200831142T patent/SI2214487T1/sl unknown
- 2008-10-10 BR BRPI0817542-0A2A patent/BRPI0817542A2/pt active Search and Examination
- 2008-10-10 CN CN200880120430XA patent/CN101896065B/zh active Active
- 2008-10-10 ES ES08838314.6T patent/ES2445444T3/es active Active
- 2008-10-10 AU AU2008310732A patent/AU2008310732B2/en not_active Ceased
- 2008-10-10 KR KR1020107010233A patent/KR101546111B1/ko active Active
- 2008-10-10 RS RS20140078A patent/RS53180B/sr unknown
- 2008-10-10 HR HRP20140105AT patent/HRP20140105T1/hr unknown
- 2008-10-10 NZ NZ584471A patent/NZ584471A/en unknown
- 2008-10-10 MX MX2010003942A patent/MX2010003942A/es active IP Right Grant
- 2008-10-10 MY MYPI2010001613A patent/MY157116A/en unknown
- 2008-10-10 EA EA201070442A patent/EA018414B1/ru not_active IP Right Cessation
- 2008-10-10 UA UAA201005720A patent/UA107444C2/uk unknown
- 2008-10-10 PL PL08838314T patent/PL2214487T3/pl unknown
- 2008-10-10 US US12/682,073 patent/US8173805B2/en active Active
- 2008-10-10 EP EP08838314.6A patent/EP2214487B1/en active Active
-
2010
- 2010-04-06 IL IL204889A patent/IL204889A/en active IP Right Grant
- 2010-04-08 MA MA32751A patent/MA31761B1/fr unknown
- 2010-04-08 ZA ZA2010/02465A patent/ZA201002465B/en unknown
- 2010-04-09 DO DO2010000101A patent/DOP2010000101A/es unknown
- 2010-04-09 US US12/757,089 patent/US8212032B2/en active Active
- 2010-05-06 CO CO10054262A patent/CO6270285A2/es active IP Right Grant
- 2010-05-11 CR CR11423A patent/CR11423A/es unknown
-
2014
- 2014-02-18 CY CY20141100122T patent/CY1114865T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028467A1 (en) * | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| WO2007106525A1 (en) * | 2006-03-13 | 2007-09-20 | The Regents Of The University Of California | Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases |
| WO2008105968A1 (en) * | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101896065B (zh) | 新的sEH抑制剂及其用途 | |
| US20100210655A1 (en) | NOVEL sEH INHIBITORS AND THEIR USE | |
| WO2009073772A1 (en) | Novel seh inhibitors and their use | |
| EP2209376B1 (en) | Novel seh inhibitors and their use | |
| WO2009070497A1 (en) | SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE | |
| EP2097378B1 (en) | Novel seh inhibitors and their use | |
| US20100324076A1 (en) | Novel sEH Inhibitors and their Use | |
| EP2240026A1 (en) | NOVEL sEH INHIBITORS AND THEIR USE | |
| EP2240025A1 (en) | NOVEL sEH INHIBITORS AND THEIR USE | |
| HK1141211B (en) | Novel seh inhibitors and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |